Last reviewed · How we verify
Tavneos (AVACOPAN)
Tavneos blocks the action of a chemical called C5a, which is involved in the body's inflammatory response.
Tavneos (AVACOPAN) is a small molecule complement 5a receptor antagonist developed by Chemocentryx. It targets the C5a anaphylatoxin chemotactic receptor 1 to treat Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis. Tavneos was FDA-approved in 2021 and is currently patented. Key safety considerations include the potential for increased risk of infections due to immunosuppression. It is a treatment option for patients with these rare and serious autoimmune disorders.
At a glance
| Generic name | AVACOPAN |
|---|---|
| Sponsor | Chemocentryx |
| Drug class | Complement 5a Receptor Antagonist [EPC] |
| Target | C5a anaphylatoxin chemotactic receptor 1 |
| Modality | Small molecule |
| Therapeutic area | Rare Disease |
| Phase | FDA-approved |
| First approval | 2021 |
| Annual revenue | 400 |
Mechanism of action
Avacopan is complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a. Avacopan blocks C5a-mediated neutrophil activation and migration. The precise mechanism by which avacopan exerts therapeutic effect in patients with ANCA-associated vasculitis has not been definitively established.
Approved indications
- Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis)
- Granulomatosis with polyangiitis
- Microscopic polyangiitis
Common side effects
- Pneumonia
- Acute kidney injury
- Urinary tract infection
- Hepatic function abnormal
- Angioedema
- Vomiting
- Diarrhea
- Nausea
- Headache
- Rash
- Fatigue
- Upper abdominal pain
Key clinical trials
- A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD) (PHASE1)
- Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV. (PHASE3)
- A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis (PHASE4)
- Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement (PHASE3)
- Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN) (PHASE2)
- TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis (PHASE2,PHASE3)
- Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis (PHASE4)
- A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tavneos CI brief — competitive landscape report
- Tavneos updates RSS · CI watch RSS
- Chemocentryx portfolio CI